The HIV-1 Transmitted Drug Resistance in Newly Confirmed and ART-Naïve HIV-1-Infected MSM in Zhenjiang City, Jiangsu, China
Estimating the prevalence and characterizing the HIV-1 transmitted drug resistance (TDR) are crucial for the prevention and control of HIV/AIDS. However, there are limited data currently on TDR among men who have sex with men (MSM) in Zhenjiang, Jiangsu, a high-risk population for drug resistance. We conducted a retrospective analysis among the newly diagnosed and antiretroviral therapy (ART)-naive HIV-1-infected MSM in Zhenjiang, 2012-2018. We analyzed the HIV-1 subtypes, TDR prevalence, TDR-associated mutations, and predicted drug sensitivity. Among these 192 participants, CRF01_AE (50.0%) and CRF07_BC (34.9%) were the predominant HIV-1 strains, with an increasing diversity of circulating subtypes (<i>p</i> < .05). A total of nine patients infected with CRF01_AE exhibited one or more TDR mutations, including 3.6% for Protease Inhibitor (PI)-related mutations, 1.0% for NRTI-related mutations and 1.0% for NNRTI-related mutations. The most common mutation was M46L/I for PIs. Notably, TDR prevalence showed an upward trend from 2012 to 2018, with an average of 4.7%. The gradually diversified subtypes, the increased TDR prevalence, and the potential risk of transmitting drug-resistant strains to the general population highlight the necessity of TDR monitoring in MSM. This will be beneficial for the prevention and control of HIV/AIDS in Zhenjiang.
Authors
- Yue Wu (ORCID: https://orcid.org/0000-0002-4668-3949)
- Xiao Y. Wu
- Xu Hong (ORCID: https://orcid.org/0000-0002-5500-918X)
- Jin Liu (ORCID: https://orcid.org/0000-0002-7752-0966)
- Jing Yang (ORCID: https://orcid.org/0000-0002-6833-8863)
- Lu Ye
- Shen Li (ORCID: https://orcid.org/0000-0002-3068-4138)
Institutions
- Xinjiang Uygur Autonomous Region Disease Prevention and Control Center (CN)
Publication Details
- Journal
- AIDS Research and Human Retroviruses
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1089/aid.2025.0032
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00